Multiple independent nested stent structures and methods for their preparation and deployment

Abstract
Blood vessels and other body lumens are stented using stent structures comprising a plurality of radially expansible rings where at least some of the rings comprise axially extending elements which interleave with axially extending elements on adjacent unconnected rings. The ring structures may be open cell structures or closed cell structures, and the axially extending elements will typically be formed as part of the open cell or closed cell structure.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates generally to medical devices and methods. More particularly, the present invention relates to apparatus and methods for delivering a plurality of separate luminal prostheses within a body lumen, such as a blood vessel.


Coronary artery disease is the leading cause of death and morbidity in the United States and Western society. In particular, atherosclerosis in the coronary arteries can cause myocardial infarction, commonly referred to as a heart attack, which can be immediately fatal or, even if survived, can cause damage to the heart which can incapacitate the patient.


While coronary artery bypass surgery can be an effective treatment for stenosed arteries resulting from atherosclerosis or other causes, it is a highly invasive procedure which is also expensive and which requires substantial hospital and recovery time. Percutaneous transluminal angioplasty, commonly referred to as balloon angioplasty, is less invasive, less traumatic, and significantly less expensive than bypass surgery. Heretofore, however, balloon angioplasty has not been considered as effective a treatment as bypass surgery. The effectiveness of balloon angioplasty, however, has improved significantly with the introduction of stenting, which involves the placement of a scaffold structure within an artery that has been treated by balloon angioplasty. The stent inhibits abrupt reclosure of the artery and has some benefit in inhibiting subsequent restenosis resulting from hyperplasia.


Presently available stents may be generally categorized as either “closed cell configurations” or “open cell configurations.” Closed cell configurations are characterized by ellipses, ovals, and polygonal structures, such as closed boxes, rhomboids, diamonds, and the like, which open in the circumferential direction and shorten in the axial direction as the stent is expanded. Open cell configurations include zigzag and serpentine structures which may be formed as a plurality of discreet rings or may be formed from a single continuous wire or other element. Closed cell stents are advantageous in that they provide better coverage of the blood vessel wall when the stent is deployed. This is particularly advantageous in tightly curved segments of the vasculature where even stent coverage in both the axial and circumferential directions on the outer wall of the vessel has been shown to reduce restenosis. Such even coverage is also an advantage in achieving uniform delivery from drug eluting stents. In contrast, open cell stent configurations are generally more flexible than the closed cell configurations. Such flexibility is advantageous in the tortuous regions of the vasculature where enhanced flexibility can provide better conformance to the vessel being treated. Better conformance can reduce the stress on the vessel wall, particularly at the stent ends, and lead to reduced restenosis.


For these reasons, it would be desirable to provide improved stents and stent structures. In particular, it would be desirable to provide stents and stent structures which combine the improved wall coverage of closed cell stent structures with the increased flexibility of open cell stent structures. It would be still further desirable if such improved stent structures allowed a physician to optimize the length of vessel being treated in accordance with the nature of the disease, allowed for the delivery of both very short and very long stent structures, and optionally permited delivery of stent structures at multiple contiguous and/or non-contiguous locations within a body lumen. At least some of these objectives will be met by the inventions described hereinafter.


2. Description of the Background Art


U.S. Pat. Nos. 6,200,337 and 5,870,381 describe stents having closed cell rings with overlapping portions connected by axial connecting members. U.S. Pat. No. 6,375,676 describes a stent having open cell rings with overlapping portions connected by axial connecting members. U.S. Patent Application Publication Nos. 2002/0188343 and 2002/0188347 describe expandable stents having interconnecting elements which interlock circumferentially adjacent bridges between axially adjacent stent segments. U.S. Pat. No. 4,580,568 describes the sequential placement of a plurality of zigzag ring stents where the stents may optionally be overlapped (FIGS. 7 and 8). U.S. Pat. No. 6,319,277 describes a stent formed from a single element into a plurality of nested “waves.” U.S. Pat. No. 5,554,181 describes a stent formed from a single element into partially overlapping windings. Other patents of interest include U.S. Pat. Nos. 6,312,458; 5,879,370; 5,755,776; 5,507,771; and 5,104,404. U.S. Pat. No. 6,258,117 B1 describes a stent having multiple sections connected by separable or frangible connecting regions. Optionally, the connecting regions are severed after the stent structure has been implanted in the blood vessel. U.S. Pat. Nos. 5,571,086; 5,776,141, and 6,143,016 describe an expandable sleeve for placement over a balloon catheter for the delivery of one or two stent structures to the vasculature. U.S. Pat. No. 5,697,948, describes a catheter for delivering stents covered by a sheath.


BRIEF SUMMARY OF THE INVENTION

The present invention provides methods and apparatus for prosthesis placement, such as stenting of body lumens, typically blood vessels, and more typically coronary arteries. The methods and systems will also find significant use in the peripheral vasculature, the cerebral vasculature, and in other ducts, such as the biliary duct, the fallopian tubes, and the like. The terms “stent” and “stenting” are defined to include any of the wide variety of expandable prostheses and scaffolds which are designed to be intraluminally introduced to a treatment site and expanded in situ to apply a radially outward force against the inner wall of the body lumen at that site. The stents and prostheses of the present invention commonly comprise a closed or, less preferably, an open lattice structure, and are typically formed from a malleable or elastic metal. When formed from a malleable metal, such as stainless steel, gold, platinum, titanium, and super alloys, the stents will typically be expanded by a balloon which causes plastic deformation of the lattice so that it remains opened after deployment. When formed from an elastic metal, including super elastic metals such as nickel-titanium alloys, the lattice structures will usually be radially constrained when delivered and deployed by releasing the structures from such radial constraint so that they “self-expand” at the target site. When the stent or lattice structures are covered with a fabric or polymeric membrane covering, they are commonly referred to as grafts. Grafts may be used for the treatment of aneurysms or other conditions which require placement of a non-permeable or semi-permeable barrier at the treatment site. The terms “stent” and “stent structures” refer broadly to all radially expansible stents, grafts, and other scaffold-like structures which are intended for deployment within body lumens.


The stents and stent structures of the present invention may have any of a variety of common constructions, including closed cell constructions such as expansible ovals, ellipses, box structures, expandable diamond structures, expandable rhomboid structures, as well as other regular and irregular polygonal structures, etc. In addition, the closed cells may have complex slotted geometries, such as H-shaped slots, I-shaped slots, J-shaped slots, etc. Suitable open cell structures include zigzag structures, serpentine structures, and the like. Such conventional stent structures are well described in the patent and medical literature. Specific examples of suitable stent structures are described in the following U.S. Patents, the full disclosures of which are incorporated herein by reference: U.S. Pat. Nos. 6,315,794; 5,980,552; 5,836,964; 5,527,354; 5,421,955; 4,886,062; and 4,776,337. Preferred structures are described herein with reference to FIGS. 4 and 5.


According to one aspect of the present invention, stents will comprise a plurality of independent expansible rings each having a length of 1 mm or greater, usually 2 mm or greater, and sometimes of 3 mm or greater, usually being in the range from 1 mm to 10 mm, typically from 2 mm to 7 mm, more typically from 2 mm to 5 mm. The use of such short ring lengths is advantageous since the overall stent length will be a multiple of the ring length.


The methods and apparatus of the present invention will provide for the deployment of a plurality of stents or other prostheses from a common stent delivery catheter. Usually, the number of delivered stents will be in the range from 2 to 50, typically from 3 to 30, and most typically from 3 to 25. As more stents are placed on the delivery catheter, the individual stent length will often be somewhat less, although this is not necessarily the case in all instances. The multiple prostheses may be deployed individually or in groups of two or more at a single location or at multiple spaced-apart locations in the body lumen or lumens.


In another aspect of the present invention, stent structures will comprise a plurality of radially expansible rings, as generally described above, arranged along an axial line. Expansible rings are arranged adjacent to each other and will include axially extending elements which interleave or nest with similarly axially extending elements on adjacent rings. By “interleaved” it is meant that the axially extending elements on adjacent rings will interpenetrate with each other in an axial direction, at least prior to stent expansion and preferably even after stent expansion. Usually, the interpenetrating elements will not overlap, i.e., be positioned one over another in the radial direction, but it is possible that in some implementations there may be some overlapping prior to or even after expansion. The axial interpenetration will be at least 0.1 mm, usually being at least 1 mm, and often being in the range from 1 mm to 5 mm, and will of course depend on the axial length(s) of the adjacent ring(s). Expressed as a percentage, the axial length of the axially extending elements will usually be at least 5% of the axial length of the ring, usually being from 5% to 50%, and preferably being from 20% to 30%.


Preferably, the axially extending elements on adjacent rings will interleave without interlocking so as to permit axial separation between the adjacent rings prior to expansion of the rings. However, axially extending elements may, in some instances, also interpenetrate in a peripheral direction prior to expansion. Such peripheral interpenetration can provide axial interlocking of the axially adjacent expansible rings prior to expansion. It will usually be desirable or even necessary that the peripheral interpenetration be relieved during radial expansion of the stent structures so that the independent rings be released from each other when deployed. In other instances, however, a tether or other types of links may be provided to interconnect or otherwise restrain the rings even after expansion and deployment.


It is not necessary that all adjacent rings be unconnected, although at least two, and preferably three, four, five, eight, ten, or more adjacent rings will be unconnected. Thus, some (but fewer than all) of the adjacent rings of the stent structures may have ties or links therebetween, including flexible or non-flexible (deflectable) ties or links. The axially adjacent rings, however, will usually not be connected, although in some cases they may have easily separable or non-permanent connections as described in more detail below. Each expansible ring will preferably comprise expansible closed cell structures, as set forth above. Less preferably, the expansible rings may comprise expansible open cell structures, as set forth above. The lengths and diameters of the individual rings have been set forth generally above. The stent structure will typically comprise from 2 to 50 individual rings, usually from 3 to 30 individual rings, and often from 3 to 25 individual rings.


The spacing between adjacent rings may be uniform or non-uniform, preferably being uniform. In some cases, it is desirable that the edges of the adjacent rings be spaced-apart by a uniform distance in the axial direction, typically at least 0.1 mm, usually being from 0.1 mm to 0.5 mm, prior to stent expansion. In other situations, it will be preferred that the adjacent rings be in contact with each other at discreet points or along continuous sections of the edges. In some cases, the stent structures will be configured to shorten upon expansion to increase the spacing between rings. It is usually preferable that the edges of the adjacent rings not overlap, at least prior to deployment. Deployment of the stents, particularly in curved and tortuous luminal regions, may sometimes result in touching and overlapping of the stent rings.


The stent structures may be modified in a variety of ways which are used with other conventional stents. For example, some or all of the radially expansible rings may releasably carry a biologically active agent, such as an agent which inhibits hyperplasia. Exemplary anti-hyperplasia agents include anti-neoplastic drugs, such as paclitaxel, methotrexate, and batimastal; antibiotics such as doxycycline, tetracycline, rapamycin, everolimus and other analogs and derivatives of rapamycin, and actinomycin; amino suppressants such as dexamethasone and methyl prednisolone; nitric oxide sources such as nitroprussides; estrogen; estradiols; and the like.


In another aspect of the present invention, a stent deployment system comprises an elongate carrier having a central axis and including a plurality of radially expansible rings arranged over a surface thereof. At least some of the radially expansible rings will have the features and characteristics just described with respect to the present invention. The elongate carriers of the stent deployment systems will typically comprise a radially expansible balloon having an outer surface where the radially expansible rings are disposed over the outer surface of the balloon. In such cases, the balloon may comprise a single inflation chamber in which case all of the rings will be expanded simultaneously. Alternatively, the balloon may comprise a plurality of independently inflatable chambers so that individual expansible rings may be deployed separately from the other rings.


The elongated carrier of the stent deployment system may alternatively comprise a carrier tube having an inner surface which carries and constrains the radially expansible rings. In such cases, the expansible rings will usually be self-expanding, i.e., held in a radially constrained configuration by the carrier tube prior to release and expansion at a luminal target site. Usually, the carrier tube structures will further comprise a pusher tube arranged to axially advance the radially expansible rings from the carrier tube. The elongated carrier may still further comprise a balloon arranged to receive and expand individual rings as they advance from the carrier tube, in which case the carrier may be used for delivering the formable (balloon-expansible) stent structures. However, such a balloon may also be used with self-expanding stent structures to control or enhance expansion, to perform predilatation of a lesion prior to stent deployment, or to further expand the stent structures and dilate the vessel lumen after the structures have self-expanded.


In a further aspect of the present invention, multiple independent stent rings are arranged on a carrier by the following methods. An elongated carrier structure is provided and a plurality of radially expansible rings comprising axially extending elements are mounted on the carrier structure such that the axially extending elements on adjacent rings interleave or nest after they are mounted. The number of rings mounted on the carrier is selected to provide a desired overall stent length, and the number of rings is typically in the ranges set forth above, providing overall stent lengths in the range from 6 mm to 120 mm, usually from 9 mm to 100 mm, and typically from 12 mm to 50 mm. Other aspects of the individual radially expansible rings have been described above.


In yet another aspect of the present invention, methods for stenting a body lumen comprise delivering to the body lumen a stent structure having a plurality of radially expansible rings. The rings are as described above with respect to other aspects of the present invention, and at least some of the rings are expanded within the body lumen so that the axially extending elements open and axially move apart from each other as they radially expand. Preferably, the length of the axially extending elements and degree of radial expansion will be selected so that the elements remain interleaved even after being fully expanded within the body lumen. Such an interleaving structure enhances the continuity of lumenal wall coverage provided by the deployed stent structure. Target body lumens are typically blood vessels, more typically arteries, such as coronary arteries. The rings may be delivered simultaneously, typically using a single inflatable balloon, or sequentially, typically using a carrier tube, pusher tube and optionally deployment balloon. Methods may be used for delivering from 3 to 50 rings, usually from 3 to 30 rings, and typically from 3 to 25 rings, to cover a luminal length in the range from 6 mm to 120 mm, usually from 9 mm to 100 mm, and typically from 12 mm to 50 mm.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic illustration of a stent structure according to the present invention comprising a plurality of closed cell ring structures.



FIG. 2 illustrates the stent structure of FIG. 1 shown in its radially expanded configuration.



FIGS. 2A and 2B illustrate the difference in deployed configuration of non-nested and nested stent structures, respectively.



FIG. 3 illustrates a stent structure constructed in accordance with the principles of the present invention comprising a plurality of open cell expansible rings.



FIG. 4 illustrates the stent structure of FIG. 3 shown in its radially expanded configuration.



FIG. 5 illustrates a first exemplary expansible ring structure in accordance with the principles of the invention.



FIG. 6 illustrates a stent structure comprising a plurality of the ring structures of FIG. 5, shown in a rolled out radially collapsed configuration.



FIGS. 6A and 6B illustrate variations on the ring structure of FIG. 6, where the variations are chosen to inhibit axial separation of the ring structures prior to deployment.



FIG. 7 illustrates the stent structure of FIG. 6 shown in its radially expanded configuration.



FIG. 8 illustrates a second exemplary expansible ring structure in accordance with the principles of the present invention.



FIG. 9 illustrates a stent structure comprising a plurality of the rings of FIG. 8.



FIG. 10 illustrates the stent structure of FIG. 8 in its radially expanded configuration.



FIGS. 11-14 illustrate further exemplary expansible ring structures in accordance with the principles of the present invention.



FIGS. 15A and 15B illustrate a further embodiment of a stent structure according to the present invention shown in unexpanded and expanded configurations, respectively.



FIGS. 16A and 16B illustrate a still further embodiment of a stent structure according to the present invention shown in unexpanded and expanded configurations, respectively.



FIGS. 17A-C illustrate deployment of a closed cell stent structure according to the present invention with both a balloon having a single chamber (FIG. 17B and a balloon having multiple chambers to permit selective delivery of portions of the stent structure (FIG. 17C).



FIGS. 18A-18D illustrate deployment of a plurality of a expansible rings which form a stent structure according to the present invention using a delivery tube and pusher tube in combination with an expansion balloon.



FIG. 19 illustrates a kit constructed in accordance with the principles of the present invention.



FIGS. 20A-20B, 21A-21B, and 22A-22B illustrate further embodiments of stent structures according to the invention in unexpanded and expanded configurations.





DETAILED DESCRIPTION OF THE INVENTION

The present invention provides apparatus, systems, and methods for preparing and delivering stent structures comprising a plurality of “separate” or “discreet” radially expansible ring segments. By “separate” or “discreet,” it is meant that the ring segments are unconnected (or easily disconnected) at the time they are delivered to a target body lumen. Usually, the ring segments will be closely packed to provide a relatively high degree of vessel wall coverage after they are expanded. By disconnecting the adjacent segments, however, such a tightly packed structured can retain a very high degree of flexibility permitting delivery and conformance in even highly torturous regions of the vasculature and other body lumens.


The ability to closely pack the expansible ring segments and achieve a high degree of vessel wall coverage is achieved at least partly because at least some of the axially adjacent rings comprise axially extending elements which interleave or nest with axially extending elements on an adjacent connected ring. Usually, the axially extending elements will be formed from a radially expansible portion of the ring, e.g., the element will be part of the closed cell structure or open cell structure as described in more detail hereinbelow. As these expansible sections will typically foreshorten as they are radially expanded, interleaving and nesting the segments on adjacent rings prior to expansion minimizes or preferably eliminates any gaps in coverage after the stent is expanded, as described in more detail below.


The stent structures of the present invention may be fabricated as either balloon-expansible or self-expanding stents according to methods well known in the art. Typical deformable materials suitable for fabricating balloon-expansible stent structures include 316L stainless steel, gold, platinum, cobalt chrome, platinum, and the like. Suitable resilient materials for self-expanding stents include nickel titanium alloys, various spring stainless steel alloys, Eligloy® alloy, and the like. It will also be possible to form the stent structures of the present invention from both natural and synthetic polymers. Natural polymers include collagen, gelatin, chitin, cellulose, and the like. Suitable synthetic polymers include polyglycolic acids (PGA), polylactic acids (PLA), poly ethylene glycols (PEG), polyamides, polyimides, polyesters, and the like. In some instances, it would be possible to form different radially expansible segments from different materials in order to achieve different properties.


The stent structures will comprise a plurality of the individual radially expansible ring segments with typical dimensions, numbers, and the like, described above in the summary. The plurality of ring segments will be arranged prior to delivery, in a manner suitable for delivery to and deployment within a target blood vessel or other body lumen. Usually, the plurality of radially expansible rings will be arranged along an axial line, typically defined by a deployment balloon, a delivery tube, or some combination thereof. The expansible ring segments will be arranged so that the axially extending elements on each of the segments is interleaved with corresponding axial extending elements on adjacent but unconnected ring segments. Referring now to FIGS. 1-4, such arrangements will be generally described for both closed cell ring structures (FIGS. 1 and 2) and open cell ring structures (FIGS. 3 and 4).


In FIG. 1, a portion of a stent structure 10 comprising a plurality of radially expansible rings 12 is illustrated. Each radially expansible ring 12 includes a plurality of closed rhomboid or diamond structures 14 circumferentially joined by connectors 16. It will appreciated that the stent structure 10 is shown in a “rolled-out” configuration, and that only a portion of the structure is depicted for simplicity. Usually, the stent structure would contain a greater number of expansible rings 12, and each ring would include a larger number of rhomboid cells.


Of particular importance to the present invention, FIG. 1 illustrates that each rhomboid cell 14 includes an axially extending element 18 which interleaves with a similar element on an adjacent ring structure. This interleaved structure permits a very close packing of the rings without the need to physically attach the rings. Moreover, when the stent structure is radially expanded, as shown in FIG. 2, the axially extending elements 18 will usually continue to axially interleave which increases the coverage of the body lumen wall being treated.


The advantages of the present invention are particularly apparent in curved blood vessels BV, as illustrated in FIGS. 2A and 2B. An expanded, non-interleaved multiple ring stent is shown in FIG. 2A. Substantial gaps G appear between the axially extending elements 18 on the large diameter side of the curved vessel segment. In contrast, the nested stent configurations of the present invention are able to maintain interleaving of the axially extending elements 18, even on the large diameter side of the curved vessel segment, as shown in FIG. 2B. While the present invention cannot assure that gaps will always be eliminated, the number and extent of the gaps will at least be reduced, thus improving wall coverage.


A similar result can be achieved with a stent structure 20 comprising a plurality of open cell zigzag ring structures 22, shown in FIGS. 3 and 4. Each zigzag ring includes axially extending elements which alternate directions, and the rings are arranged so that the elements are “nested” as shown in FIG. 3. After radially expansion of the stent structure 20, the nested axially extending elements of the rings 22 remain generally overlapping, as shown in FIG. 4, even when the stent has undergone significant radial expansion. While prior stent structures have utilized nested zigzag structures, they have generally either connected adjacent structures or utilized only a single filament for forming such structures. In neither case can the flexibility achieved by the present invention in combination with the ability to selectively deliver independent radially expansible segments be achieved.


Referring now to FIGS. 5-7, a particular stent structure 30 comprising a plurality of radially expansible rings 32 is illustrated. Each ring 32, as shown in FIG. 5, comprises a plurality of closed cell boxes 34 joined at their midpoints by circumferentially directed connectors 36. Each box 34 includes a central opening 35 which is generally an axial cut enlarged at each end and in the middle. As with prior illustrations, the ring structure 32 is shown in its rolled-out or flattened configurations. In the actual stent structure, the ring would be rolled so that the “broken” connectors 34′ are in fact connected to form a cylindrical shape. The “bow tie” shape of the central opening 35 is advantageous as it permits maximum radial compression of the stent while minimizing both the delivery profile and the stress relief of the stent during expansion in the body lumen.



FIG. 6 illustrates the very tight packing of the stent structure 30 that can be achieved. The stent structure 30 in FIG. 6 is in its pre-deployment configuration as it would be when placed over a balloon or within a delivery tube, as described in more detail hereinbelow. It can be seen that virtually all of the available area for carrying the stent is covered. Thus, when the stent is expanded as shown in FIG. 7, the area of the blood vessel or other luminal wall will be maximized. Moreover, this very close packing of the stent is achieved while concurrently providing a very high degree of flexibility while the stent is being delivered and conformability after the stent is deployed. Such flexibility results in large part from the fact that the adjacent rings are unconnected and free to move relative to each other as the stent is delivered and deployed. Coverage in curved vessels will be improved with the specific design of FIGS. 6 and 7 generally as shown in FIGS. 2A and 2B.


Axial separation of the rings 32 of stent structure 30 can be inhibited by modifying the ring geometries in a variety of ways, such as shown in FIGS. 6A and 6B. In FIG. 6A, the boxes 34a are fabricated (or deformed after fabrication) to collapse near the centers so that they form “bow tie” structures, with enlarged ends 34b interlocking. Alternatively, the boxes 34c can be inclined relative to the axial direction, as shown in FIG. 6B, to also provide interlocking of adjacent rings prior to deployment. Such inclination can be used with at least most of the embodiments of the present invention to improve axial retention. In addition, other patterns, such as chevrons, interleaved sigmoidal shapes, and the like could also be used to provide the desired interlocking prior to stent expansion.


Referring now to FIGS. 8-10, a similar degree of wall coverage and flexibility can be achieved with open cell stent structures. Stent structure 40 (FIG. 9) comprises a plurality of open cell expansible rings 42 formed in a “castellated” pattern, as shown in more detail in FIG. 8. The castellations comprise narrow U-shaped loops 44 and 46 which alternatively extend in a right hand direction (loop 44) and left hand direction (loop 46) relative to a circumferential center line 48. The rings 42 are arranged so that the loops 44 and 46 overlap, as shown in FIG. 9, to form a tightly packed configuration. When expanded, as shown in FIG. 9, the loops 44 and 46 continue to overlap to provide a very high degree of vessel wall coverage, as shown in FIG. 10. The open cell configuration of FIGS. 8-10 will also improve coverage in curved vessels, minimizing gaps as discussed previously. The length of the open cells will be in the range from 0.5 to 10 mm, usually from 2 to 5 mm.


Referring now to FIGS. 11-14, additional embodiments of the radially expansible ring segments are illustrated. As with prior illustrations, the ring segments are shown in their pre-deployed configuration in a rolled-out manner. Ring structure 50 of FIG. 11 comprises a plurality of closed cell box elements 52 joined by circumferential connectors 54 and 56. Ring 50 is similar to ring 32 of FIG. 5, except that the circumferential connectors 54 are split to form H-shaped slots 55 which span pairs of adjacent box structures 52 and the intermediate connectors 54 form a single, larger cell structures. Such larger openings are advantageous when stenting in blood vessels with side branches which must be kept open. In particular, the side branches may be accessed by opening the slots 55 with a balloon structure. In contrast, the cell pattern of stent 32 (FIG. 5) provides a greater coverage that may be of particular importance with drug eluting stents.


Stent structures comprising multiple rings 50 are shown in their unexpanded and expanded configuration in FIGS. 11A and 11B, respectively. Of particular note, the open slots 55 (FIG. 11B) provide for significant additional expansion (via balloon dilation or other subsequent intervention) in order to provide access to a side branch or for any other purpose. A further expanded slot 55 is shown in FIG. 11C, as expanded by balloon B.


Ring structure 60 of FIG. 12 comprises a plurality of interconnected box structures 62, 64, and 66. Each of the box structures shares common axial struts or beams, but the axially offset nature of the three box structures permits radial expansion. Moreover, the box structures 62 and 66 provide the axially extending elements which may be interleaved in forming a stent structure from a plurality of the rings 60. Axially extending elements 62 and 66 interleave and mate so that interleaved extending elements of adjacent stents can be interference fit with each other to provide a friction fit which inhibits separation of the stents, or be kept out of contact to allow for separation. Furthermore, extending elements can deflect radially inward which will provide additional adherence to an expandable delivery balloon and increased stent retention.


Ring structure 70 in FIG. 13 comprises paired, symmetric box structures 72 and 74 joined by short circumferential connectors 76. Each of the box structures 72 and 74 define a long and a short axially extending member which can be aligned with each other when forming a stent structure from a plurality of the rings 70. This particular structure will provide good adherence to an expandable delivery balloon during deployment and have many of the same advantages as the embodiment of FIG. 12.


Ring structure 80 of FIG. 14 is similar to that of ring structure 70 of FIG. 13, except that the “longer” rings terminate in a retainer, such as T-ends 82. When deploying multiple rings 80 in a stent structure, the T-ends will interlock to help hold the ring in place on the balloon or within the delivery tube. The interlock, however, does not provide a permanent attachment and, adjacent ring segments 80 will naturally release from each other during deployment. Moreover, since the interlocking structures are not actually attached, they permit a high degree of flexibility while the stent is being deployed. While T-ends are shown in FIG. 14, the terminal retainers could be L- or J-shaped ends or have any other geometry, which also provides for interlocking In particular, each of these geometries will include a peripherally extending segment 83 which interlocks with a peripherally extending segment 83 on an adjacent T-end 82. Upon expansion of the ring 80, the segment 83 will move apart allowing the adjacent rings to deploy separately. When deploying multiple rings 80 in a stent structure, the T-, L- or J-ends will interlock to help hold the ring in place on the balloon or within the delivery tube. The interlock, however, does not provide a permanent attachment and, adjacent ring segments 80 will naturally release from each other during deployment. Such interlocking could also incorporated in the embodiments of FIGS. 5, 8, 11 and 12.


As illustrated thus far, the stent structures have generally maximized to vessel wall coverage achieved after expansion. While this will often be desired, in some instances it may be desired to lessen the amount of wall coverage. The stent structures shown in FIGS. 15A and 15B and FIGS. 16A and 16B, achieve such reduced wall coverage by providing “spacers” between adjacent rings.


In FIG. 15A, a stent structure 90 includes independent rings 92 having boxes 93 circumferentially separated by spacers 94. The spacers 94 will either not expand or expand only after the boxes 93 have expanded, thus maintaining an axial distance D between adjacent rings after expansion, as shown in FIG. 15B. The distance D will be equal to about one-half the total axial length of the spacer 94.


Stent structure 96 (FIGS. 16A and 16B) is similar to structure 90, except that spaces 97 are axially split to define an H-shaped cell (as discussed with earlier embodiments) and certain of the rings 98 and joined by sigmoidal links 99.


Stent structures according to the present invention may be delivered in a variety of ways. As illustrated in FIGS. 17A-17C, the stent structure 30 may be delivered on a balloon catheter 90 having a balloon 92 with a single inflation chamber. Deployment of the stent 30 is illustrated in FIG. 17B where all independent ring structures 32 are expanded simultaneously. Alternatively, as illustrated in FIG. 17C, catheter may carry a balloon 94 having a plurality of independently inflatable compartments. In that way, one or more of the independent compartments may be inflated separately from others of the compartments to selectively deploy one, two, three, or more of the independent ring structures 32. In that case, others of the ring structures 32 will remain unexpanded and available for separate expansion or may be simply removed from the patient if unused.


Referring now to FIGS. 18A-18D, an alternative stent structure delivery protocol employing a carrier tube will be described. Such delivery protocols are described in more detail in co-pending application Ser. No. 10/306,813, filed on Nov. 27, 2002, and in copending application Ser. No. 10/637,713, filed Aug. 8, 2003, the full disclosures of which are incorporated herein by reference. Catheter 160 (FIG. 18A) comprises a sheath 164, pusher tube 166, and a catheter body 168. The catheter body 168 includes an expansible balloon 170 over its distal portion. Individual expansible rings, as described above, are deployed, as illustrated in FIGS. 18B and 18C, by first advancing the distal-most ring 162 using the pusher tube 166. The catheter body 168 is also distally advanced so that a distal portion of the balloon 170 lies within the distal-most deployed ring 162, as shown in FIG. 18B. The remaining proximal portion of the balloon 170 will, of course, remain within the other rings 162 which themselves remain within the sheath 164. The balloon 170 is then inflated, but only the advanced distal portion of the balloon inflates within the advanced ring 162, as illustrated in FIG. 18C. Expansion of the remaining proximal portion of the balloon is prevented by the sheath 164. Similarly, the remaining rings 162 remain unexpanded since they remain within the sheath 164.


Referring now to FIG. 18D, additional rings 162 may be deployed, either at the same target location within the blood vessel or at a different, spaced-apart locations within the blood vessel. Deployment of two rings 162 is illustrated. The two rings 162 are axially advanced using the pusher tube 162 so that they are positioned over the uninflated balloon 170. The balloon 170 is then inflated, as illustrated in FIG. 18D, thus expanding the rings 162 within the blood vessel BV. It will be appreciated that the catheter 160 could carry many more than the four illustrated rings 162, and three, four, five, ten, and even 20 or more individual rings could be deployed at one time, with additional single prostheses or groups of prostheses being deployed at different times and/or at different locations within the blood vessel. The use of “stent valves” as described in application Ser. No. 10/306,813, previously incorporated herein by reference, may preferably be employed to facilitate controlling the number of rings deployed and the spacing between the deployed and undeployed rings.


Referring now to FIG. 13, kits 200 according to the present invention comprise a catheter 160 (or a balloon catheter) in combination with instructions for use IFU. The instructions for use set forth any of the methods of the present invention, and in particular set forth how the catheter 160 may be used to implant a stent structure comprising multiple rings within a blood vessel or other body lumen. The catheter 160 and instructions for use will typically be packaged together, for example within a conventional package 202, such as a box, tube, pouch, tray, or the like. Catheter 160 will typically be maintained in a sterile condition within the package 202. The instructions for use may be provided on a package insert, may be printed in whole or in part on the packaging, or may be provided in other ways, such as electronically over the internet, on an electronic medium, such as a CD, DVD, or the like.


A further alternative stent structure according to the invention is illustrated in FIGS. 20A-20B. FIG. 20A illustrates a portion of a stent segment 201 in an unexpanded configuration, shown in a planar shape for clarity. Stent segment 201 comprises two parallel rows 203A, 203B of I-shaped cells 205 formed around an axis A so that stent segment 201 has a cylindrical shape. The terms “I-shaped” and “H-shaped” as used herein may refer to a similar cell geometry comprising two generally parallel slots connected by an interconnecting slot. Such cells may appear H-shaped when axis A is in a vertical orientation, or I-shaped axis A is in a horizontal orientation. Each cell 205 has upper and lower axial slots 207 aligned with the axial direction and a circumferential slot 204. Upper and lower slots 207 preferably have an oval, racetrack, rectangular or other oblong shape with a long dimension L generally parallel to axis A and a short dimension W perpendicular thereto. Axial slots 207 are bounded by upper axial struts 206A and lower axial struts 206B, curved outer ends 208 and curved inner ends 210. Each circumferential slot 204 is bounded by an outer circumferential strut 209 and an inner circumferential strut 211. Each I-shaped cell 205 is connected to the adjacent I-shaped cell 205 in the same row 98A or 98B by a circumferential connecting strut 213. All or a portion of cells 205 in row 98A merge or join with cells 205 in row 98B at the inner ends 210, which are integrally formed with the inner ends 210 of the adjacent cells 205.


Stent segment 201 is configured to interleave with an adjacent stent segment of similar construction. Upper and lower axial struts 206A, 206B and outer ends 208 form axial elements E that are received in the spaces S between each element E of the adjacent stent segment 201.


In a preferred embodiment, a spacing member 212 extends outwardly in the axial direction from a selected number of outer circumferential struts 209 and/or connecting struts 213. Spacing member 212 preferably itself forms a subcell 214 in its interior, but alternatively may be solid without any cell or opening therein. For those spacing members 212 attached to outer circumferential struts 209, subcell 214 preferably communicates with I-shaped cell 205. Spacing members 212 are configured to engage the curved outer ends 208 of an adjacent stent segment 201 so as to maintain appropriate spacing between adjacent stent segments. In one embodiment, spacing members 212 have outer ends 216 with two spaced-apart protrusions 218 that provide a cradle-like structure to index and stabilize the curved outer end 208 of the adjacent stent segment. Preferably, spacing members 212 have an axial length of at least about 10%, more preferably at least about 25%, of the long dimension L of I-shaped cells 205, so that the I-shaped cells 205 of adjacent stent segments are spaced apart at least that distance. This results in elements E interleaving a distance of at least about 10%, preferably at least about 25%, and more preferably at least about 50% of their axial length as measured from the circumferential connecting struts 213. Because spacing members 212 experience little or no axial shortening during expansion of stent segments 201, this minimum spacing between stent segments is maintained both in the unexpanded and expanded configurations.



FIG. 20B shows stent segment 201 of FIG. 20A in an expanded configuration. It may be seen that cells 205 are expanded so that upper and lower slots 207 are diamond shaped with circumferential slots 204 remaining basically unchanged. This results in some axial shortening of the stent segment, thereby increasing the spacing between adjacent stent segments. The stent geometry is optimized by balancing the amount of axial shortening and associated inter-segment spacing, the desired degree of vessel wall coverage, the desired metal density, and other factors. Because the stent is comprised of multiple unconnected stent segments 201, any desired number from 2 up to 10 or more stent segments may be deployed simultaneously to treat lesions of any length from 2 mm up to 100 mm or more. Further, because such segments are unconnected to each other, the deployed stent structure is highly flexible and capable of deployment in long lesions having curves and other complex shapes.


As an additional feature, circumferential slots 204 provide a pathway through which vessel side branches can be accessed for catheter interventions. Should stent segment 201 be deployed at a location in which it covers the ostium of a side branch to which access is desired, a balloon dilatation catheter may be positioned through circumferential slot 204 and expanded. This deforms circumferential struts 209, 211 axially outward, thereby expanding circumferential slot 204 and further expanding upper and lower slots 207, as shown in phantom in FIG. 20B. This provides a relatively large opening 220 through which a catheter may be inserted through stent segment 201 and into the side branch for placing stents, performing angioplasty, or carrying out other interventions.



FIGS. 21A-21B illustrate a second embodiment of a stent segment 201′ according to the invention. In FIG. 21A, two stent segments 201′ are shown interleaved in a planar shape for clarity. Similar to the embodiment of FIG. 20A, stent segment 201′ comprises two parallel rows 222A, 222B of I-shaped cells 224 formed into a cylindrical shape around axial axis A. Cells 224 have upper and lower axial slots 226 and a connecting circumferential slot 228. Upper and lower axial slots 226 are bounded by upper axial struts 230, lower axial struts 232, curved outer ends 234, and curved inner ends 236, forming axial elements E configured to be received in spaces S between elements E in the adjacent stent segment 201′. Circumferential slots 228 are bounded by an outer circumferential strut 238 and inner circumferential strut 240. Each I-shaped cell 224 is connected to the adjacent I-shaped cell 224 in the same row 222 by a circumferential connecting strut 242. Row 222A is connected to row 222B by the merger or joining of curved inner ends 236 of at least one and preferably two of slots 226 in each row 222.


One of the differences between the embodiment of FIGS. 21A-21B and that of FIGS. 20A-20B is the way in which spacing is maintained between the adjacent interleaved stent segments. In place of the spacing members 212 of the earlier embodiment, the embodiment of FIG. 21A includes a bulge 244 in upper and lower axial struts 230, 232 extending circumferentially outwardly from axial slots 226. These give axial slots 226 an arrowhead or cross shape at their inner and outer ends. The bulge 244 in each upper axial strut 230 extends toward the bulge 244 in a lower axial strut 232 in the same cell 205 or in an adjacent cell 205, thus narrowing the space S therebetween and creating a concave abutment 246 in the space between each axial slot 226. Concave abutments 246 are configured to receive and engage curved outer ends 234 of cells 224 in the adjacent stent segment, thereby maintaining spacing between the stent segments. The axial location of bulges 244 along upper and lower axial struts 230, 232 may be selected to provide the desired degree of inter-segment spacing. Preferably, the axial depth of concave abutments 246 from curved outer ends 234 is at least about 10% of the axial length of elements E (measured from circumferential struts 242), preferably at least about 25% of the axial length of elements E, and more preferably at least about 50% of the axial length of elements E.



FIG. 21B shows two stent segments 201 of FIG. 21A in an expanded condition. It may be seen that axial slots 226 are deformed into a circumferentially-widened modified diamond shape with bulges 244 on the now diagonal upper and lower axial struts 230, 232. Circumferential slots 228 are generally the same size and shape as in the unexpanded configuration. Bulges 244 have been pulled away from each other to some extent, but still provide a concave abutment 246 to maintain a minimum degree of spacing between adjacent stent segments. As in the earlier embodiment, some axial shortening of each segment occurs upon expansion and stent geometry can be optimized to provide the ideal intersegment spacing.


In a preferred embodiment, stent segments 201′ retain some degree of interleaving in the expanded configuration, with outer ends 234 of elements E on adjacent stent segments being at least circumferentially aligned with each other, and preferably extending into spaces S of the adjacent stent segment a distance of at least about 1%, more preferably at least about 5%, and in some cases at least about 10% of the axial length of elements E as measured from circumferential connecting struts 242. In one exemplary embodiment, for a stent segment 201′ having an axial length of 4 mm and an unexpanded diameter of about 0.5-1.5 mm, elements E have an axial length of about 1 mm and are interleaved a distance Du of about 0.1-0.5 mm in the unexpanded configuration. Segments 201′ are expandable to a diameter of 2.5-3.5 mm and elements E are interleaved a distance De of about 0.01-0.1 mm in the expanded configuration.


It should also be noted that the embodiment of FIGS. 21A-21B retains the feature described above with respect to FIGS. 20A-20B to enable access to vessel side branches blocked by stent segment 201′. Should such side branch access be desired, a dilatation catheter may be inserted into circumferential slot 228 and expanded to provide an enlarged opening through which a side branch may be entered.



FIGS. 22A-22B illustrate a variant of the stent structure of FIGS. 21A-21B that has a larger expanded diameter. The primary difference in the embodiment of FIGS. 22A-22B is the geometry of the inner ends 236′ of each axial slot 226′. Rather than being curved, inner ends 236′ are generally straight and oriented in the circumferential direction. Because of the longer circumferential dimension of the inner ends 236′, an inner portion 250 of each axial strut 230′, 232′ is disposed at an angle relative to the axial direction, giving the inner half 252 of each axial slot 226′ a trapezoidal shape. Again, bulges 244′ are disposed along axial struts 230′, 232′ so as to create concave abutments 246′ that engage the outer ends 234′ of axial slots 226′ and maintain inter-segment spacing.


As shown in FIG. 22B, stent segment 201″ expands to a configuration similar to that of FIG. 21B, with the exception that inner ends 236′ remain generally straight and aligned with the circumferential direction. Axial slots 226′ are again expanded into a modified diamond shape, with bulges 244′ extending into spaces S to maintain inter-segment spacing. In an exemplary embodiment, stent segment 201″ has a length of about 4 mm and diameter of about 1.0-2.0 mm when unexpanded, and is expandable to a diameter of about 3.0-4.0 mm.


The stent structures of the invention are preferably radiopaque so as to be visible by means of fluoroscopy. Radiopaque markers and/or materials may be used in or on the stent structures. Markers of radiopaque materials may be applied to the exterior of the stents, e.g, by applying a metal such as gold, platinum, a radiopaque polymer, or other suitable coating or mark on all or a portion of the stents. Alternatively, the stent structures may include a radiopaque cladding or coating or may be composed of radiopaque materials such as MP35N (ASTM 562), L-605 cobalt chromium (ASTM F90), other suitable alloys containing radiopaque elements, or multilayered materials having radiopaque layers. As a further option, the stent structures may have a geometry conducive to fluoroscopic visualization, such as having struts of greater thickness, sections of higher density, or overlapping struts. Some of the possible materials that may be used in the stent segments, either alone or in combination, include (by ASTM number):

  • F67-00 Unalloyed Titanium
  • F75-01 Cobalt-28 Chromium-6 Molybdenum Alloy
  • F90-01 Wrought Cobalt-20 Chromium-15 Tungsten-10 Nickel Alloy
  • F136-02a Wrought Titanium-6 Aluminum-4 Vanadium ELI Alloy
  • F138-00, F139-00 Wrought 18 Chromium-14 Nickel-2.5 Molybdenum Stainless Steel Bar or Sheet
  • F560-98 Unalloyed Tantalum
  • F562-02 Wrought 35 Cobalt-35 Nickel-20 Chromium-10 Molybdenum Alloy
  • F563-00 Wrought Cobalt-20 Nickel-20 Chromium 3.5 Molybdenum-3.5 Tungste-5 Iron Alloy
  • F688 Wrought Cobalt-35 Nickel-20 Chromium-10 Molybdenum Alloy
  • F745-00 18 Chromium-12.5 Nickel-2.5 Molybdenum Stainless Steel
  • F799-02 Cobalt-28 Chromium-6 Molybdenum Alloy
  • F961-96 Cobalt-35 Nickel-20 Chromium-10 Molybdenum Alloy
  • F1058-02 Wrought 40 Cobalt-20 Chromium-16 Iron-15 Nickel-7 Molybdenum Alloy
  • F1091-02 Wrought Cobalt-20 Chromium-15 Tungsten-10 Nickel Alloy
  • F1108 Titanium-6 Aluminum-4 Vanadium Alloy
  • F1295-01 Wrought Titanium-6 Aluminum-7 Niobium Alloy
  • F1314-01 Wrought Nitrogen-strengthened 22 Chromium-13 Nickel-5 Manganese-2.5 Molybdenum Stainless Steel Alloy
  • F1241-99 Unalloyed Titanium Wire
  • F1350-02 Wrought 18 Chromium-14 Nickel-2.5 Molybdenum Stainless Steel Wire
  • F1377-98a Cobalt-28 Chromium-6 Molybdenum Powder coating
  • F1472-02a Wrought Titanium-6 Aluminum-4 Vanadium Alloy
  • F1537-00 Wrought Cobalt-28 Chromium-6 Molybdenum Alloy
  • F1580-01 Titanium and Titanium-6 Aluminum-4 Vanadium Alloy Powder coating
  • F1586-02 Wrought Nitrogen Strengthened 21 Chromium-10 Nickel-3 Mnaganese-2.5 Molybdenum Stainless Steel Bar
  • F1713-96 Wrought Titanium-13 Niobium-13 Zirconium Alloy
  • F1813-01 Wrought Titanium-12 Molybdenum-6 Zirconium-2 Iron Alloy
  • F2063-00 Wrought Nickel-Titanium Shape Memory Alloys
  • F2066-01 Wrought Titanium-15 Molybdenum Alloy
  • F2146-01 Wrought Titanium-3 Aluminum-2.5 Vanadium Alloy Seamless Tubing
  • F2181-02a Wrought Stainless Steel Tubing


The preferred embodiments of the invention are described above in detail for the purpose of setting forth a complete disclosure and for the sake of explanation and clarity. Those skilled in the art will envision other modifications within the scope and sprit of the present disclosure.

Claims
  • 1. A method for arranging multiple independent stent rings on a carrier of a catheter, said method comprising: providing an elongated carrier structure; andmounting a plurality of radially expansible rings comprising axially extending elements on the carrier structure with the rings in an unexpanded crimped configuration suitable for delivery into a blood vessel and at least some of the rings are separable from an adjacent ring, wherein the axially extending elements on adjacent rings interleave when mounted on the carrier structure in the unexpanded crimped configuration without interlocking so as to permit axial separation of the adjacent rings, none of the axially extending elements constraining axial separation of the adjacent rings in the unexpanded crimped configuration, wherein the axially extending elements having an overlapping portion which is received between axially extending elements of an adjacent ring, the overlapping portion comprising a pair of axial struts separated by a circumferential distance which is constant or tapering toward the adjacent ring throughout all of the overlapping portion, wherein at least some of the axially extending elements comprise expansible closed structures which widen as the rings are expanded and wherein at least some of the axially separable rings further comprise spacers which engage the axially extending elements on adjacent rings to provide a preselected spacing between adjacent rings upon radial expansion, wherein adjacent axially extending elements form a concave region therebetween, the concave region having a closed end and the spacers maintaining a gap between the closed end and an axially extending element of the adjacent ring, wherein the spacers comprise an axially extending strut having an axial extension length, the axially extending strut being disposed between two adjacent axially extending elements on the same ring, the two adjacent axially extending elements having an axial length greater than the axial extension length of the strut.
  • 2. A method as in claim 1, wherein the number of rings mounted on the carrier structure is selected to provide a desired overall stent length.
  • 3. A method as in claim 2, wherein the number of rings is from two to 50 and the overall stent length is in the range from 2 mm to 200 mm.
  • 4. A method as in claim 1, wherein the expansible closed structures are selected from the group consisting of boxes, rhomboids, ovals, ellipses, diamonds, and irregular polygons.
  • 5. A method as in claim 1, wherein the expansible closed structures are defined by a slot pattern selected from the group consisting of I-patterns and H-patterns, and J-patterns.
  • 6. A method as in claim 1, wherein the radially expansible rings are configured to axially shorten upon expansion.
  • 7. A method as in claim 1, wherein the axially extending elements remain interleaved following expansion.
  • 8. A method as in claim 1, wherein the axially extending elements axially interleave over a distance of at least 0.1 mm prior to stent expansion.
  • 9. A method as in claim 8, wherein the distance is in the range from 1 mm to 5 mm.
  • 10. A method as in claim 1, wherein the rings have axial lengths in range from 1 mm to 10 mm, prior to radial expansion.
  • 11. A method as in claim 10, wherein the rings have axial lengths in the range from 0.9 mm to 9 mm after radial expansion.
  • 12. A method as in claim 11 consisting of from two to 50 expansible ring structures.
  • 13. A method as in claim 1, wherein the radially expansible rings releasably carry a biologically active agent.
  • 14. A method as in claim 13, wherein the biologically active agent inhibits hyperplasia.
  • 15. A method as in claim 14, wherein the biologically active agent is selected from the group consisting of anti-neoplastic drugs including paclitaxel, methotrexate and batimastal; antibiotics including doxycycline, tetracycline, rapamycin, and actinomycin; immunosuppressants including dexamethasone and methyl prednisolone; nitric oxide sources including nitroprussides; estrogen; and estradiols.
  • 16. A method as in claim 1, further comprising covering at least a portion of the rings with a carrier tube coupled to the carrier structure.
  • 17. A method as in claim 1, wherein the rings are mounted on an elongated balloon coupled to the carrier structure.
  • 18. A method as in claim 17, wherein the rings are axially slidable on the elongated balloon.
  • 19. A method as in claim 1, wherein the spacer comprises a cradle structure adapted to receive an axially extending element on an adjacent ring.
  • 20. A method as in claim 1, wherein the spacer comprises a concave abutment.
CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 12/492,828 filed Jun. 26, 2009 which is a continuation of U.S. patent application Ser. No. 10/738,666 filed Dec. 16, 2003 which claims the priority benefit of U.S. Provisional Patent Application No. 60/440,839, filed Jan. 17, 2003, each of which the entire contents are incorporated herein by reference.

US Referenced Citations (504)
Number Name Date Kind
4069825 Akiyama Jan 1978 A
4468224 Enzmann et al. Aug 1984 A
4512338 Balko Apr 1985 A
4564014 Fogarty et al. Jan 1986 A
4580568 Gianturco Apr 1986 A
4681110 Wiktor Jul 1987 A
4690684 McGreevy et al. Sep 1987 A
4733665 Palmaz Mar 1988 A
4739762 Palmaz Apr 1988 A
4748982 Horzewski et al. Jun 1988 A
4762129 Bonzel Aug 1988 A
4770176 McGreevy et al. Sep 1988 A
4775337 Van Wagener et al. Oct 1988 A
4776337 Palmaz Oct 1988 A
4886062 Wiktor Dec 1989 A
4891225 Langer et al. Jan 1990 A
4950227 Savin et al. Aug 1990 A
4988356 Crittenden et al. Jan 1991 A
4994066 Voss Feb 1991 A
4994069 Ritchart et al. Feb 1991 A
4994298 Yasuda Feb 1991 A
5013318 Spranza, III May 1991 A
5035706 Giantureo et al. Jul 1991 A
5040548 Yock Aug 1991 A
5061273 Yock Oct 1991 A
5064435 Porter Nov 1991 A
5092877 Pinchuk Mar 1992 A
5102417 Palmaz Apr 1992 A
5104404 Wolff Apr 1992 A
5122154 Rhodes Jun 1992 A
5135535 Kramer Aug 1992 A
5158548 Lau et al. Oct 1992 A
5192297 Hull Mar 1993 A
5195984 Schatz Mar 1993 A
5201757 Heyn et al. Apr 1993 A
5217495 Kaplan et al. Jun 1993 A
5219355 Parodi et al. Jun 1993 A
5226913 Pinchuk Jul 1993 A
5246421 Saab Sep 1993 A
5273536 Savas Dec 1993 A
5282824 Gianturco Feb 1994 A
5300085 Yock Apr 1994 A
5312415 Palermo May 1994 A
5328469 Coletti Jul 1994 A
5334187 Fischell et al. Aug 1994 A
5391172 Williams et al. Feb 1995 A
5421955 Lau et al. Jun 1995 A
5443498 Fontaine Aug 1995 A
5445646 Euteneuer et al. Aug 1995 A
5456713 Chuter Oct 1995 A
5458615 Klemm et al. Oct 1995 A
5470315 Adams Nov 1995 A
5478349 Nicholas Dec 1995 A
5490837 Blaeser et al. Feb 1996 A
5496346 Horzewski et al. Mar 1996 A
5501227 Yock Mar 1996 A
5507768 Lau et al. Apr 1996 A
5507771 Gianturco Apr 1996 A
5514093 Ellis et al. May 1996 A
5514154 Lau et al. May 1996 A
5527354 Fontaine et al. Jun 1996 A
5531735 Thompson Jul 1996 A
5533968 Muni et al. Jul 1996 A
5534007 St. Germain et al. Jul 1996 A
5545209 Roberts et al. Aug 1996 A
5549551 Peacock, III et al. Aug 1996 A
5549563 Kronner Aug 1996 A
5549635 Solar Aug 1996 A
5554181 Das Sep 1996 A
5562725 Schmitt et al. Oct 1996 A
5571086 Kaplan Nov 1996 A
5591195 Taheri et al. Jan 1997 A
5593412 Martinez et al. Jan 1997 A
5607444 Lam Mar 1997 A
5607463 Schwartz et al. Mar 1997 A
5628755 Heller et al. May 1997 A
5628775 Jackson et al. May 1997 A
5634928 Fischell et al. Jun 1997 A
5639274 Fischell et al. Jun 1997 A
5662675 Polanskyj Stockert et al. Sep 1997 A
5662703 Yurek et al. Sep 1997 A
5670161 Healy et al. Sep 1997 A
5676654 Ellis et al. Oct 1997 A
5683451 Lenker et al. Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5693085 Buirge et al. Dec 1997 A
5697948 Marin Dec 1997 A
5697971 Fischell et al. Dec 1997 A
5702418 Ravenscroft Dec 1997 A
5702419 Berry et al. Dec 1997 A
5709701 Parodi Jan 1998 A
5716393 Lindenberg et al. Feb 1998 A
5722669 Shimizu et al. Mar 1998 A
5723003 Winston et al. Mar 1998 A
5735869 Fernandez-Aceytuno Apr 1998 A
5741323 Pathak et al. Apr 1998 A
5749848 Jang et al. May 1998 A
5749921 Lenker et al. May 1998 A
5755772 Evans et al. May 1998 A
5755776 Al-Saadon May 1998 A
5755781 Jayaraman May 1998 A
5769882 Fogarty et al. Jun 1998 A
5772669 Vrba Jun 1998 A
5776141 Klein et al. Jul 1998 A
5792144 Fischell et al. Aug 1998 A
5797951 Mueller et al. Aug 1998 A
5800519 Sandock Sep 1998 A
5807398 Shaknovich Sep 1998 A
5824040 Cox et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5833694 Poncet Nov 1998 A
5836964 Richter et al. Nov 1998 A
5843092 Heller et al. Dec 1998 A
5855563 Kaplan et al. Jan 1999 A
5858556 Eckert et al. Jan 1999 A
5870381 Kawasaki et al. Feb 1999 A
5879370 Fischell et al. Mar 1999 A
5891190 Boneau Apr 1999 A
5895398 Wensel et al. Apr 1999 A
5899935 Ding May 1999 A
5902332 Schatz May 1999 A
5919175 Sirhan Jul 1999 A
5921971 Agro et al. Jul 1999 A
5922020 Klein et al. Jul 1999 A
5941869 Patterson et al. Aug 1999 A
5951585 Cathcart et al. Sep 1999 A
5961536 Mickley et al. Oct 1999 A
5968069 Dusbabek et al. Oct 1999 A
5972027 Johnson Oct 1999 A
5976107 Mertens et al. Nov 1999 A
5976155 Foreman et al. Nov 1999 A
5980484 Ressemann et al. Nov 1999 A
5980486 Enger Nov 1999 A
5980514 Kupiecki et al. Nov 1999 A
5980552 Pinchasik Nov 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
5989280 Euteneuer et al. Nov 1999 A
5993484 Shmulewitz Nov 1999 A
5997563 Kretzers et al. Dec 1999 A
6004328 Solar Dec 1999 A
6007517 Anderson Dec 1999 A
6010530 Goicoechea Jan 2000 A
6022359 Frantzen Feb 2000 A
6022374 Imran Feb 2000 A
6027519 Stanford Feb 2000 A
6033434 Borghi Mar 2000 A
6036725 Avellanet Mar 2000 A
6039721 Johnson et al. Mar 2000 A
6042589 Marianne Mar 2000 A
6056722 Jayaraman May 2000 A
6063111 Hieshima et al. May 2000 A
6066155 Amann et al. May 2000 A
6068655 Seguin et al. May 2000 A
6070589 Keith et al. Jun 2000 A
6090063 Makower et al. Jul 2000 A
6090136 McDonald et al. Jul 2000 A
6102942 Ahari Aug 2000 A
6106530 Harada Aug 2000 A
RE36857 Euteneuer et al. Sep 2000 E
6120522 Vrba et al. Sep 2000 A
6123712 Di Caprio et al. Sep 2000 A
6123723 Konya et al. Sep 2000 A
6126685 Lenker et al. Oct 2000 A
6129756 Kugler Oct 2000 A
6132460 Thompson Oct 2000 A
6139572 Campbell et al. Oct 2000 A
6143016 Bleam et al. Nov 2000 A
6165167 Delaloye Dec 2000 A
6165210 Lau et al. Dec 2000 A
6171334 Cox Jan 2001 B1
6179878 Duering Jan 2001 B1
6183509 Dibie Feb 2001 B1
6187034 Frantzen Feb 2001 B1
6190402 Horton et al. Feb 2001 B1
6196995 Fagan Mar 2001 B1
6200337 Moriuchi et al. Mar 2001 B1
6217585 Houser et al. Apr 2001 B1
6238991 Suzuki May 2001 B1
6241691 Ferrera et al. Jun 2001 B1
6241758 Cox Jun 2001 B1
6248122 Klumb et al. Jun 2001 B1
6251132 Ravenscroft et al. Jun 2001 B1
6251134 Alt et al. Jun 2001 B1
6254612 Hieshima Jul 2001 B1
6254628 Wallace et al. Jul 2001 B1
6258117 Camrud Jul 2001 B1
6264688 Herklotz et al. Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6270524 Kim Aug 2001 B1
6273895 Pinchuk et al. Aug 2001 B1
6273911 Cox et al. Aug 2001 B1
6273913 Wright et al. Aug 2001 B1
6287291 Bigus et al. Sep 2001 B1
6312458 Golds Nov 2001 B1
6315794 Richter Nov 2001 B1
6319277 Rudnick et al. Nov 2001 B1
6322586 Monroe et al. Nov 2001 B1
6325823 Horzewski et al. Dec 2001 B1
6334871 Dor et al. Jan 2002 B1
6340366 Wijay Jan 2002 B2
6344272 Oldenburg et al. Feb 2002 B1
6348065 Brown et al. Feb 2002 B1
6350252 Ray et al. Feb 2002 B2
6350277 Kocur Feb 2002 B1
6357104 Myers Mar 2002 B1
6361558 Hieshima et al. Mar 2002 B1
6375676 Cox Apr 2002 B1
6379365 Diaz Apr 2002 B1
6383171 Gifford et al. May 2002 B1
6409753 Brown et al. Jun 2002 B1
6415696 Erickson et al. Jul 2002 B1
6416543 Hilaire et al. Jul 2002 B1
6419693 Fariabi Jul 2002 B1
6425898 Wilson et al. Jul 2002 B1
6428811 West et al. Aug 2002 B1
6451025 Jervis Sep 2002 B1
6451050 Rudakov et al. Sep 2002 B1
6464720 Boatman et al. Oct 2002 B2
6468298 Pelton Oct 2002 B1
6468299 Stack et al. Oct 2002 B2
6485510 Camrud et al. Nov 2002 B1
6488694 Lau et al. Dec 2002 B1
6488702 Besselink Dec 2002 B1
6511468 Cragg et al. Jan 2003 B1
6520986 Martin et al. Feb 2003 B2
6520987 Plante Feb 2003 B1
6527789 Lau et al. Mar 2003 B1
6527799 Shanley Mar 2003 B2
6530944 West et al. Mar 2003 B2
6540777 Stenzel Apr 2003 B2
6551350 Thornton et al. Apr 2003 B1
6555157 Hossainy Apr 2003 B1
6558415 Thompson May 2003 B2
6562067 Mathis May 2003 B2
6569180 Sirhan et al. May 2003 B1
6575993 Yock Jun 2003 B1
6579305 Lashinski Jun 2003 B1
6579309 Loos et al. Jun 2003 B1
6582394 Reiss et al. Jun 2003 B1
6582460 Cryer Jun 2003 B1
6585756 Strecker Jul 2003 B1
6589273 McDermott Jul 2003 B1
6592549 Gerdts et al. Jul 2003 B2
6599296 Gillick et al. Jul 2003 B1
6599314 Mathis Jul 2003 B2
6602226 Smith et al. Aug 2003 B1
6602282 Yan Aug 2003 B1
6605062 Hurley et al. Aug 2003 B1
6605109 Fiedler Aug 2003 B2
6607553 Healy et al. Aug 2003 B1
6613074 Mitelberg et al. Sep 2003 B1
6629992 Bigus et al. Oct 2003 B2
6645517 West Nov 2003 B2
6645547 Shekalim et al. Nov 2003 B1
6656212 Ravenscroft et al. Dec 2003 B2
6660031 Tran et al. Dec 2003 B2
6660381 Halas et al. Dec 2003 B2
6663660 Dusbabek et al. Dec 2003 B2
6666883 Seguin et al. Dec 2003 B1
6676693 Belding et al. Jan 2004 B1
6676695 Solem Jan 2004 B2
6679909 McIntosh et al. Jan 2004 B2
6685730 West et al. Feb 2004 B2
6692465 Kramer Feb 2004 B2
6699280 Camrud et al. Mar 2004 B2
6699281 Vallana et al. Mar 2004 B2
6699724 West et al. Mar 2004 B1
6702843 Brown Mar 2004 B1
6709379 Brandau et al. Mar 2004 B1
6709440 Callol et al. Mar 2004 B2
6712827 Ellis et al. Mar 2004 B2
6712845 Hossainy Mar 2004 B2
6723071 Gerdts et al. Apr 2004 B2
6736842 Healy et al. May 2004 B2
6743219 Dwyer et al. Jun 2004 B1
6743251 Eder Jun 2004 B1
6761734 Suhr Jul 2004 B2
6776771 Van Moorlegem et al. Aug 2004 B2
6778316 Halas et al. Aug 2004 B2
6790227 Burgermeister Sep 2004 B2
6800065 Duane et al. Oct 2004 B2
6825203 Pasternak et al. Nov 2004 B2
6837901 Rabkin et al. Jan 2005 B2
6849084 Rabkin et al. Feb 2005 B2
6852252 Halas et al. Feb 2005 B2
6855125 Shanley Feb 2005 B2
6858034 Hijlkema et al. Feb 2005 B1
6878161 Lenker Apr 2005 B2
6884257 Cox Apr 2005 B1
6893417 Gribbons et al. May 2005 B2
6896695 Mueller et al. May 2005 B2
6899728 Phillips et al. May 2005 B1
6913619 Brown et al. Jul 2005 B2
6918928 Wolinsky et al. Jul 2005 B2
6939376 Shulz et al. Sep 2005 B2
6945989 Betelia et al. Sep 2005 B1
6945995 Nicholas Sep 2005 B2
6951053 Padilla et al. Oct 2005 B2
6962603 Brown et al. Nov 2005 B1
6964676 Gerberding et al. Nov 2005 B1
6991646 Clerc et al. Jan 2006 B2
6994721 Israel Feb 2006 B2
7005454 Brocchini et al. Feb 2006 B2
7022132 Kocur Apr 2006 B2
7029493 Majercak et al. Apr 2006 B2
7037327 Salmon et al. May 2006 B2
7090694 Morris et al. Aug 2006 B1
7101840 Brocchini et al. Sep 2006 B2
7131993 Gregorich Nov 2006 B2
7137993 Acosta et al. Nov 2006 B2
7141063 White et al. Nov 2006 B2
7147655 Chermoni Dec 2006 B2
7147656 Andreas et al. Dec 2006 B2
7169172 Levine et al. Jan 2007 B2
7169174 Fischell et al. Jan 2007 B2
7172620 Gilson Feb 2007 B2
7175654 Bonsignore et al. Feb 2007 B2
7182779 Acosta et al. Feb 2007 B2
7192440 Andreas et al. Mar 2007 B2
7208001 Coyle et al. Apr 2007 B2
7220275 Davidson et al. May 2007 B2
7220755 Betts et al. May 2007 B2
7223283 Chouinard May 2007 B2
7238197 Sequin et al. Jul 2007 B2
7241308 Andreas et al. Jul 2007 B2
7244336 Fischer et al. Jul 2007 B2
7270668 Andreas et al. Sep 2007 B2
7294146 Chew et al. Nov 2007 B2
7300456 Andreas et al. Nov 2007 B2
7309350 Landreville et al. Dec 2007 B2
7314480 Eidenschink et al. Jan 2008 B2
7320702 Hammersmark et al. Jan 2008 B2
7323006 Andreas et al. Jan 2008 B2
7326236 Andreas et al. Feb 2008 B2
7351255 Andreas Apr 2008 B2
7918881 Andreas et al. Apr 2011 B2
7993388 Lee et al. Aug 2011 B2
8282680 Kao et al. Oct 2012 B2
8317850 Kusleika Nov 2012 B2
20010020154 Bigus et al. Sep 2001 A1
20010020173 Klumb et al. Sep 2001 A1
20010020181 Layne Sep 2001 A1
20010035902 Iddan et al. Nov 2001 A1
20010044595 Reydel et al. Nov 2001 A1
20010044632 Daniel et al. Nov 2001 A1
20010049547 Moore Dec 2001 A1
20020007212 Brown et al. Jan 2002 A1
20020035395 Sugimoto Mar 2002 A1
20020037358 Barry et al. Mar 2002 A1
20020045914 Roberts et al. Apr 2002 A1
20020052642 Cox et al. May 2002 A1
20020091439 Baker et al. Jul 2002 A1
20020092536 LaFontaine et al. Jul 2002 A1
20020107560 Richter Aug 2002 A1
20020111671 Stenzel Aug 2002 A1
20020123786 Gittings et al. Sep 2002 A1
20020128706 Ospyka Sep 2002 A1
20020138132 Brown Sep 2002 A1
20020151924 Shiber Oct 2002 A1
20020151955 Tran et al. Oct 2002 A1
20020156496 Chermoni Oct 2002 A1
20020165599 Nasralla Nov 2002 A1
20020168317 Daighighian et al. Nov 2002 A1
20020177890 Lenker Nov 2002 A1
20020183763 Callol et al. Dec 2002 A1
20020188343 Mathis Dec 2002 A1
20020188347 Mathis Dec 2002 A1
20020193873 Brucker et al. Dec 2002 A1
20030045923 Bashiri et al. Mar 2003 A1
20030093143 Zhao et al. May 2003 A1
20030097169 Brucker et al. May 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030114919 McQuiston et al. Jun 2003 A1
20030114922 Iwasaka et al. Jun 2003 A1
20030125791 Sequin et al. Jul 2003 A1
20030125800 Shulze et al. Jul 2003 A1
20030125802 Callol et al. Jul 2003 A1
20030135259 Simso Jul 2003 A1
20030135266 Chew et al. Jul 2003 A1
20030139796 Sequin et al. Jul 2003 A1
20030139797 Johnson et al. Jul 2003 A1
20030139798 Brown et al. Jul 2003 A1
20030163085 Tanner et al. Aug 2003 A1
20030176909 Kusleika Sep 2003 A1
20030191516 Weldon et al. Oct 2003 A1
20030195609 Berenstein Oct 2003 A1
20030199821 Gerdts et al. Oct 2003 A1
20030204238 Tedeschi Oct 2003 A1
20030208223 Kleiner Nov 2003 A1
20030212447 Euteneuer Nov 2003 A1
20030225446 Hartley Dec 2003 A1
20040015224 Armstrong et al. Jan 2004 A1
20040024450 Shulze et al. Feb 2004 A1
20040030380 Shulze et al. Feb 2004 A1
20040044395 Nelson Mar 2004 A1
20040073290 Chouinard Apr 2004 A1
20040088044 Brown et al. May 2004 A1
20040093061 Acosta et al. May 2004 A1
20040093067 Israel May 2004 A1
20040098081 Landreville et al. May 2004 A1
20040106979 Goicoechea Jun 2004 A1
20040111145 Serino et al. Jun 2004 A1
20040117008 Wnendt et al. Jun 2004 A1
20040143322 Litvack et al. Jul 2004 A1
20040176832 Hartley et al. Sep 2004 A1
20040181239 Dorn et al. Sep 2004 A1
20040186551 Kao et al. Sep 2004 A1
20040193245 Deem et al. Sep 2004 A1
20040215165 Coyle et al. Oct 2004 A1
20040215312 Andreas et al. Oct 2004 A1
20040215331 Chew et al. Oct 2004 A1
20040230285 Gifford, III et al. Nov 2004 A1
20040243217 Andersen et al. Dec 2004 A1
20040249434 Andreas et al. Dec 2004 A1
20040249439 Richter et al. Dec 2004 A1
20050004657 Burgermeister Jan 2005 A1
20050010276 Acosta et al. Jan 2005 A1
20050038494 Eidenschink Feb 2005 A1
20050038505 Shulze et al. Feb 2005 A1
20050049673 Andreas et al. Mar 2005 A1
20050080474 Andreas et al. Apr 2005 A1
20050080475 Andreas et al. Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050123451 Nomura Jun 2005 A1
20050125051 Eidenschink et al. Jun 2005 A1
20050131008 Betts et al. Jun 2005 A1
20050137622 Griffin Jun 2005 A1
20050143827 Globerman et al. Jun 2005 A1
20050149168 Gregorich Jul 2005 A1
20050165378 Heinrich et al. Jul 2005 A1
20050182477 White Aug 2005 A1
20050209674 Kutscher et al. Sep 2005 A1
20050222671 Schaeffer et al. Oct 2005 A1
20050228477 Grainger et al. Oct 2005 A1
20050245637 Hossainy et al. Nov 2005 A1
20050249777 Michal et al. Nov 2005 A1
20050278011 Peckham Dec 2005 A1
20050288764 Snow et al. Dec 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060069424 Acosta et al. Mar 2006 A1
20060173529 Blank Aug 2006 A1
20060200223 Andreas et al. Sep 2006 A1
20060206190 Chermoni Sep 2006 A1
20060229700 Acosta et al. Oct 2006 A1
20060229706 Shulze et al. Oct 2006 A1
20060271150 Andreas et al. Nov 2006 A1
20060271151 McGarry et al. Nov 2006 A1
20060282147 Andreas Dec 2006 A1
20060282149 Kao Dec 2006 A1
20060282150 Olson et al. Dec 2006 A1
20060287726 Segal et al. Dec 2006 A1
20070010869 Sano Jan 2007 A1
20070027521 Andreas et al. Feb 2007 A1
20070043419 Nikolchev et al. Feb 2007 A1
20070067012 George et al. Mar 2007 A1
20070088368 Acosta et al. Apr 2007 A1
20070088420 Andreas et al. Apr 2007 A1
20070088422 Chew et al. Apr 2007 A1
20070100423 Acosta et al. May 2007 A1
20070100424 Chew et al. May 2007 A1
20070106365 Andreas et al. May 2007 A1
20070118202 Chermoni May 2007 A1
20070118203 Chermoni May 2007 A1
20070118204 Chermoni May 2007 A1
20070129733 Will et al. Jun 2007 A1
20070135906 Badylak et al. Jun 2007 A1
20070156225 George et al. Jul 2007 A1
20070156226 Chew et al. Jul 2007 A1
20070179587 Acosta et al. Aug 2007 A1
20070219612 Andreas et al. Sep 2007 A1
20070219613 Kao et al. Sep 2007 A1
20070265637 Andreas et al. Nov 2007 A1
20070270936 Andreas et al. Nov 2007 A1
20070276461 Andreas et al. Nov 2007 A1
20070281117 Kaplan et al. Dec 2007 A1
20070292518 Ludwig Dec 2007 A1
20080004690 Robaina Jan 2008 A1
20080046067 Toyokawa Feb 2008 A1
20080071345 Hammersmark et al. Mar 2008 A1
20080077229 Andreas et al. Mar 2008 A1
20080091257 Andreas et al. Apr 2008 A1
20080097299 Andreas et al. Apr 2008 A1
20080097574 Andreas et al. Apr 2008 A1
20080125850 Andreas et al. May 2008 A1
20080132989 Snow et al. Jun 2008 A1
20080147162 Andreas et al. Jun 2008 A1
20080177369 Will et al. Jul 2008 A1
20080199510 Ruane et al. Aug 2008 A1
20080208311 Kao et al. Aug 2008 A1
20080208318 Kao et al. Aug 2008 A1
20080234795 Snow et al. Sep 2008 A1
20080234798 Chew et al. Sep 2008 A1
20080234799 Acosta et al. Sep 2008 A1
20080243225 Satasiya et al. Oct 2008 A1
20080249607 Webster et al. Oct 2008 A1
20080269865 Snow et al. Oct 2008 A1
20090076584 Mao et al. Mar 2009 A1
20090105686 Snow et al. Apr 2009 A1
20090149863 Andreas et al. Jun 2009 A1
20090234428 Snow et al. Sep 2009 A1
20090248137 Andersen et al. Oct 2009 A1
20090248140 Gerberding Oct 2009 A1
20090276030 Kusleika Nov 2009 A1
20100004729 Chew et al. Jan 2010 A1
Foreign Referenced Citations (82)
Number Date Country
1 953 1659 Mar 1997 DE
1 963 0469 Jan 1998 DE
199 50 756 Aug 2000 DE
101 03 000 Aug 2002 DE
0 203 945 Dec 1986 EP
0 274 129 Jul 1988 EP
0 282 143 Sep 1988 EP
0 364 787 Apr 1990 EP
0 505 686 Sep 1992 EP
0 533 960 Mar 1993 EP
0 596 145 May 1994 EP
0 696 447 Feb 1996 EP
0 714 640 Jun 1996 EP
0 797 963 Jan 1997 EP
0 947 180 Oct 1999 EP
1 258 230 Nov 2002 EP
1 266 638 Dec 2002 EP
1 277 449 Jan 2003 EP
1 290 987 Mar 2003 EP
1 318 765 Jun 2003 EP
1 523 959 Apr 2005 EP
1 523 960 Apr 2005 EP
2277875 Nov 1994 GB
03-133446 Jun 1991 JP
07-132148 May 1995 JP
10-503663 Apr 1998 JP
10-295823 Nov 1998 JP
2001-190687 Jul 2001 JP
2002-538932 Nov 2002 JP
2004-121343 Apr 2004 JP
9427667 Dec 1994 WO
9526695 Oct 1995 WO
9529647 Nov 1995 WO
9626689 Sep 1996 WO
9633677 Oct 1996 WO
9637167 Nov 1996 WO
9639077 Dec 1996 WO
9710778 Mar 1997 WO
9746174 Dec 1997 WO
9748351 Dec 1997 WO
9820810 May 1998 WO
9837833 Sep 1998 WO
9858600 Dec 1998 WO
9901087 Jan 1999 WO
9965421 Dec 1999 WO
0012832 Mar 2000 WO
0015151 Mar 2000 WO
0025841 May 2000 WO
0032136 Jun 2000 WO
0041649 Jul 2000 WO
0050116 Aug 2000 WO
0051525 Sep 2000 WO
0056237 Sep 2000 WO
0062708 Oct 2000 WO
0072780 Dec 2000 WO
0126707 Apr 2001 WO
0134063 May 2001 WO
0170297 Sep 2001 WO
0191918 Dec 2001 WO
02060344 Aug 2002 WO
02085253 Oct 2002 WO
02098326 Dec 2002 WO
03022178 Mar 2003 WO
03047651 Jun 2003 WO
03051425 Jun 2003 WO
03075797 Sep 2003 WO
2004017865 Mar 2004 WO
2004043299 May 2004 WO
2004043301 May 2004 WO
2004043510 May 2004 WO
2004052237 Jun 2004 WO
2004087006 Oct 2004 WO
2004091441 Oct 2004 WO
2005009295 Feb 2005 WO
2005013853 Feb 2005 WO
2005023153 Mar 2005 WO
2006036939 Apr 2006 WO
2006047520 May 2006 WO
2007035805 Mar 2007 WO
2007053187 May 2007 WO
2007146411 Dec 2007 WO
2008005111 Jan 2008 WO
Non-Patent Literature Citations (47)
Entry
Chu et al., “Preparation of Thermo-Responsive Core-Shell Microcapsules with a Porous Membrane and Poly(N-isopropylacrylamide) Gates,” J Membrane Sci, Oct. 15, 2001; 192(1-2):27-39.
Colombo, “The Invatec Bifurcation Stent Solution” Bifurcation Stents: Novel Solutions, TCT 2003, Washington: Sep. 15-19, 2003, 24 pages total.
Cooley et al., “Applications of Ink-Jet Printing Technology to BioMEMs and Microfluidic Systems,” Proceedings, SPIE Conference on Microfluidics and BioMEMs, (Oct. 2001).
“Drug Delivery Stent With Holes Located on Neutral Axis” Research Disclosure, Kenneth Mason Publications, Hampshire, CB, No. 429, Jan. 2000, p. 13, XP00976354.
Evans Analytical Group, “Functional Sites on Non-polymeric Materials: Gas Plasma Treatment and Surface Analysis,” http://www.eaglabs.com.
Joung et al., “Estrogen Release from Metallic Stent Surface for the Prevention of Restenosis,” Journal of Controlled Release 92 (2003) pp. 83-91.
Lefevre et al. “Approach to Coronary Bifurcation Stenting in 2003,” Euro PCR, (May 2003) 28 pages total.
“STENT”. Definitions from Dictionary.com. Unabridged 9v1.01). Retrieved Sep. 22, 2006, from Dictionary.com website: <http://dictionary.reference.com/search?q=stent>.
Stimpson et al., Parallel Production of Oligonucleotide Arrays Using Membranes and Reagent Jet Printing, BioTechniques 25:886-890 (Nov. 1998).
Tilley , “Biolimus A9-Eluting Stent Shows Promise,” Medscape Medical News, Oct. 5, 2004; retrieved from the internet: <http://www.medscape.com/viewarticle/490621>, 2 pages total.
Weir et al., “Degradation of poly-L-lactide. Part 2: increased temperature accelerated degradation,” Proc Inst Mech Eng H. 2004;218(5):321-30.
International Search Report of PCT/US2002/038810, dated Apr. 1, 2003, 1 page.
International Search Report of PCT/US2002/038845, dated Mar. 2003, 2 pages.
Supplementary European Search Report of EP Patent Application No. 02804509, dated Dec. 13, 2006, 1 page total.
Supplementary European Search Report of EP Patent Application No. 04749567, dated Sep. 11, 2006, 3 pages total.
Supplementary European Search Report of EP Patent Application No. 05727731.1, dated Mar. 25, 2008, 2 pages total.
Supplementary European Search Report of EP Patent Application No. 05744136, dated Mar. 26, 2008, 3 pages total.
U.S. Appl. No. 60/336,607, filed Dec. 3, 2001, first named inventor: Bernard Andreas.
U.S. Appl. No. 60/336,767, filed Dec. 3, 2001, first named inventor: Bernard Andreas.
U.S. Appl. No. 60/336,967, filed Dec. 3, 2001, first named inventor: Sunmi Chew.
U.S. Appl. No. 60/364,389, filed Mar. 13, 2002, first named inventor: Sunmi Chew.
U.S. Appl. No. 60/440,839, filed Jan. 17, 2003, first named inventor: Bernard Andreas.
U.S. Appl. No. 60/561,041, filed Apr. 9, 2004, first named inventor: Jeffry Grainger.
U.S. Appl. No. 60/784,309, filed Mar. 20, 2006, first named inventor: Bernard Andreas.
U.S. Appl. No. 60/810,522, filed Jun. 2, 2006, first named inventor: Stephen Kaplan.
U.S. Appl. No. 60/890,703, filed Feb. 20, 2007, first named inventor: Patrick Ruane.
U.S. Appl. No. 61/012,317, filed Dec. 7, 2007, first named inventor: Patrick Ruane.
U.S. Appl. No. 09/097,855, filed Jun. 15, 1998, first named inventor: Enrique J. Klein; Abandoned.
U.S. Appl. No. 09/225,364, filed Jan. 4, 1999, first named inventor: Aaron V. Kaplan; Abandoned.
U.S. Appl. No. 10/874,859, filed Jun. 22, 2004, first named inventor: Pablo Acosta.; Abandoned.
U.S. Appl. No. 11/462,951, filed Aug. 7, 2006, first named inventor: David Snow.
U.S. Appl. No. 11/627,096, filed Jan. 25, 2007, first named inventor: Bernard Andreas.
U.S. Appl. No. 11/689,927, filed Mar. 22, 2007, first named inventor: David Snow.
U.S. Appl. No. 11/771,929, filed Jun. 29, 2007, first named inventor: David Snow.
U.S. Appl. No. 11/857,562, filed Sep. 19, 2007, first named inventor: Bryan Mao.
U.S. Appl. No. 11/938,730, filed Nov. 12, 2007, first named inventor: Sunmi Chew.
U.S. Appl. No. 11/945,142, filed Nov. 26, 2007, first named inventor: Bernard Andreas.
U.S. Appl. No. 11/947,677, filed Nov. 29, 2007, first named inventor: Dan Hammersmark.
U.S. Appl. No. 11/952,644, filed Dec. 7, 2007, first named inventor: Bernard Andreas.
U.S. Appl. No. 12/033,586, filed Feb. 19, 2008, first named inventor: Patrick H. Ruane.
U.S. Appl. No. 12/043,513, filed Mar. 6, 2008, first named inventor: David Lowe.
U.S. Appl. No. 12/040,598, filed Feb. 29, 2008, first named inventor: Bernard Andreas.
U.S. Appl. No. 12/057,527, filed Mar. 28, 2008, first named inventor: Allan Will.
U.S. Appl. No. 12/061,951, filed Apr. 3, 2008, first named inventor: Stephen Kao.
U.S. Appl. No. 12/109,477, filed Apr. 25, 2008, first named inventor: Stephen Kao.
U.S. Appl. No. 12/127,147, filed May 27, 2008, first named inventor: Sunmi Chew.
U.S. Appl. No. 12/133,909, filed Jun. 5, 2008, first named inventor: David Sanderson.
Related Publications (1)
Number Date Country
20130060321 A1 Mar 2013 US
Provisional Applications (1)
Number Date Country
60440839 Jan 2003 US
Divisions (1)
Number Date Country
Parent 12492828 Jun 2009 US
Child 13599957 US
Continuations (1)
Number Date Country
Parent 10738666 Dec 2003 US
Child 12492828 US